Ask about this productRelated genes to: HER2 protein
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 protein
Related articles to: HER2 protein
- Gallbladder cancer (GBC) is the most aggressive and lethal malignancy of the biliary tract, characterized by rapid disease progression, early invasion, and poor survival rates. The unfavorable prognosis is primarily attributed to delayed diagnosis, nonspecific clinical manifestations, and limited effective therapeutic options. Although GBC is relatively uncommon worldwide, its incidence demonstrates considerable geographic variation, with particularly high prevalence observed in South Asian countries, especially northern India, Chile, and certain regions of East Asia. Chronic gallstone disease, persistent inflammation, and environmental factors significantly contribute to disease development. - Source: PubMed
Publication date: 2026/09/30
Ramanan GunasekarKumari S SarojUmasankar JeevaShanmugam YokeshRavikumar Lokeshvar - Central nervous system (CNS) metastases represent a complication in solid tumors and often harbour unique genomic alterations diverging from those in primary tumor tissue or plasma; however, direct sampling of CNS lesions carries procedural risks, limiting its molecular profiling. The main aim of the present analysis was to assess the feasibility of Cerebrospinal Fluid (CSF) ctDNA profiling and to descriptively compare genomic alterations detected in matched tumor tissue, plasma, and CSF samples, including in patients with leptomeningeal metastases (LM). - Source: PubMed
Publication date: 2026/08/31
Arecco LucaRothé FrançoiseVenet DavidGombos AndreaGonçalves AnthonyDe Maio D'Esposito EleonoraBarthélémy PhilippeVanhaudenarde VincentClatot FlorianHolbrechts StephaneDuhoux Francois PBorcoman EdithCheymol ClaireGligorov JosephDenys HanneloreClement Paul MPunie KevinDuhem CarolineDecoster LoreCanon Jean-LucLefranc FlorenceRasschaert MarikaKindt NadègeČular KatarinaGentile GabriellaPaulus KristantoPop ElisabethDelaroche Dianede Azambuja EvandroAwada AhmadKotecki Nuria - Overexpression human epidermal growth factor receptor 2 (HER-2) has been identified as a key oncogenic driver in metastatic colorectal cancer (mCRC), detected in between 2% and 5% of the overall mCRC population, with a higher prevalence identified in RAS/RAF/PI3KCA wild-type patients. Optimal targeted interventions are seldom administered to patients with HER2-positive mCRC due to the absence of definitive anti-HER2 therapeutic regimens in the refractory setting. As a result, for patients who have undergone multiple lines of therapy-particularly those with cetuximab resistance driven by ERBB2 amplification-mediated bypass activation-treatment strategies are frequently confined to best palliative care or participation in clinical trials. - Source: PubMed
Publication date: 2026/09/21
Meng LinZhang WanqianSun ChaoqunQu XiujuanChen Ying - Accurate detection of estrogen and progesterone receptors (ER/PR), HER2, and Ki-67 is essential for molecular classification of breast cancer and in deciding upon tailored treatment. In many low- and middle-income countries (LMICs), access to histopathology and immunohistochemistry (IHC) is limited. STRAT4, an automated RT-qPCR assay performed on the widely available GeneXpert platform, offers a potential alternative. We evaluated the performance of STRAT4 on core biopsy, unstained smear of fine-needle aspiration biopsy (FNAB-US), and cellblock samples compared with conventional IHC in 178 histopathology-confirmed breast cancer patients. - Source: PubMed
Basu ParthaTalukdar AnuradhaMukherjee PoulomeMuwonge RichardLucas EricDeka Monoj KumarBal AmanjitGautam UpasanaRohilla ManishBansal BaneetSingla VeenuKhare SiddhantCarvalho Andre LopesGadgil AnitaKannan RaviSrinivasan Radhika - Early-onset colorectal cancer (EOCRC) is increasing worldwide and represents a biologically and clinically heterogeneous disease that requires precision approaches extending beyond conventional single-gene biomarkers. Recent analyses of receptor tyrosine kinase-RAS (RTK-RAS) pathway alterations demonstrate that their clinical significance is strongly dependent on age at diagnosis, ancestry, and treatment exposure. In particular, RTK-RAS alterations have been associated with unfavorable survival in untreated early-onset non-Hispanic White colorectal cancer, while an opposite association has been observed in FOLFOX-treated late-onset disease. At the same time, overall RTK-RAS pathway alteration frequencies remain relatively stable across patient groups, whereas gene-specific differences involving ERBB2, NF1, FGFR2, NTRK2, and other pathway components reveal substantial molecular heterogeneity. These observations challenge the use of RTK-RAS alteration status as a uniform prognostic biomarker and instead support a context-dependent model in which genomic alterations interact with age-related tumor biology, treatment pressures, ancestry-associated factors, and broader molecular states. Emerging genomic studies further suggest that EOCRC may harbor distinct mutational processes related to earlier-life exposures, reinforcing the need to integrate pathway alterations with mutational signatures, tumor microenvironment features, and multi-omic information. Artificial intelligence-enabled platforms such as AI-HOPE, developed at the Velazquez-Villarreal Lab at City of Hope, provide a scalable strategy for interrogating these complex multidimensional relationships through rapid cohort construction and hypothesis generation, while maintaining conventional statistical and experimental validation as essential components of inference. Future studies incorporating diverse populations, detailed treatment histories, genomic ancestry, longitudinal sampling, and functional validation will be critical for determining whether context-specific RTK-RAS patterns can ultimately improve risk stratification and therapeutic selection in EOCRC. - Source: PubMed
Velazquez-Villarreal Enrique